A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder

Journal of Clinical Psychiatry

Volumn 74, Issue 7, 2013, Pages

  Cusin, Cristina ^a   Iovieno, Nadia ^a   Iosifescu, Dan V ^b   Nierenberg, Andrew A ^a   Fava, Maurizio ^a   Rush, A John ^c   Perlis, Roy H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRAMIPEXOLE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; COORDINATION DISORDER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALAISE; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; ORGASM DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; URINARY FREQUENCY; XEROSTOMIA;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; BENZOTHIAZOLES; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84881062207     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.12m08093     Document Type: Article

References (34)

1. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR. D Study Team. Evaluation of outcomes with citalopram for depression using measurement based care in STAR.D: implications for clinical practice. Am J-Psychiatry. 2006; 163(1):28-40.
2. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224-236.
3. El Khalii N, Joyce M, Atkinson S, et al. Extended release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double blind, placebo controlled study. Int J Neuropsychopharmacol. 2010;13(7):917-932.
4. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double blind, placebo controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197-206.
5. Komossa K, Depping AM, Gaudchau A, et al. Second generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010;(12):CD008121.
6. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Washington, DC: American Psychiatric Association; 2010.
7. Zisook S, Rush AJ, Haight BR, et al. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry. 2006;59(3):203-210.
8. Fava M, Thase ME, DeBattista C. A multicenter, placebo controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66(1):85-93.
9. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo controlled proof of concept study. Biol Psychiatry. 2004;56 (1):54-60.
10. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol. 1997;12(suppl 3):57-S14.
11. Lammers CH, Diaz J, Schwartz JC, et al. Selective increase of dopamine D3-receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry. 2000;5(4):378-388.
12. Pallis E, Thermos K, Spyraki C. Chronic desipramine treatment selectively potentiates somatostatin induced dopamine release in the nucleus accumbens. Eur J Neurosci. 2001;14(4):763-767.
13. Willner P, Hale AS, Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord. 2005;86(1):37-45.
14. Mierau J, Schneider FJ, Ensinger HA, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3-and D4-receptors. Eur J Pharmacol. 1995;290(1):29-36.
15. Schneider CS, Mierau J. Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine. J Med Chem. 1987;30(3):494-498.
16. Maj J, Rogói Z, Margas 'N, et al. The effect of repeated treatment with pramipexole on the central dopamine D3-system. J Neural Transm. 2000;107(12):1369-1379.
17. Maj J, Rogóz Z. Synergistic effect of pramipexole and sertraline in the forced swimming test. Pol J Pharmacol. 1999;51-(6) :471-475.
18. Maj J, Rogóz Z, Skuza G, et al. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol. 1997;324(1) :31-37.
19. Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry. 2000;12(3):137-140.
20. DeBattista C, Solvason HB, Breen JA, et al. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol. 2000;20(2):274-275.
21. Inoue T, Kitaichi Y, Masui T, et al. Pramipexole for stage 2-treatment resistant major depression: an open study. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(8):1446-1449.
22. Szegedi A, Hillert A, Wetzel H, et al. Pramipexole, a dopamine agonist, in major depression: antidepressant effects and tolerability in an open label study with multiple doses. Clin Neuropharmacol. 1997;20:536-S45.
23. Lattanzi L, Dell'Osso L, Cassano P, et al. Pramipexole in treatment resistant depression: a 16-week naturalistic study. Bipolar Disord. 2002;4(5):307-314.
24. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000;11(2):58-65.
25. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double blind, placebo controlled trial of pramipexole added to mood stabilizers for treatment resistant bipolar depression. Am J Psychiatry. 2004;161(3):564-566.
26. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
27. Chandler GM, losifescu DV, Pollack MH, et al. RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322-325.
28. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM IV Axis I Disorders Patient Edition (SCID lIP). New York, NY: Biometrics Research, New York State Psychiatric Institute; 1995.
29. Guy W ECDEU Assessment Manualfor Psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
30. Rush AJ, Carmody T, Reimitz PE. The Inventory of Depressive Symptomatology (IDS): clinician (IDS C) and self report (IDS SR) ratings of depressive symptoms. Int J Methods Psychiatr Res. 2000;9(2) :45-59.
31. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician rating (IDS C) and Self Report (IDS SR), and the Quick Inventory of Depressive Symptomatology, Clinician rating (QIDS C) and Self Report (QIDS SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34(1):73-82.
32. Mallinckrodt CH, Kaiser CJ, Watkin JG, et al. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood based repeated measures compared with last observation carried forward ANOVA. Clin Trials. 2004;1(6):477-489.
33. Thase ME, Rush AJ. Treatment resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1081-1097.
34. Power RA, Muthen B, Henigsberg N, et al. Non random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder. J Psychiatr Res. 2012;46(10):1333-1338.